Skip to main content Accessibility help
×
Home
  • Print publication year: 2013
  • Online publication date: August 2013

Chapter 21 - Clues to ovarian tumors: new concepts of symptoms, signs, syndromes, and paraneoplastic syndromes

References

1. Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer. 2000;89:2068–75.
2. Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007;109:221–7.
3. Kim Y. A hospital-based case-control study of identifying ovarian cancer using symptom index. J Gynecol Oncol. 2010;21:65.
4. Rufford BD, Jacobs IJ, Menon U. Feasibility of screening for ovarian cancer using symptoms as selection criteria. BJOG. 2007;114:59–64.
5. Pitts MK, Heywood W, Ryall R, et al. High prevalence of symptoms associated with ovarian cancer among Australian women. Aust N Z J Obstet Gynaecol. 2011;51:71–8.
6. Bankhead CR, Kehow ST, Austoker J. Symptoms associated with diagnosis of ovarian cancer: a systematic review. BJOG. 2005;112:857–65.
7. Chan YM, Ng TY, Lee PW, Ngan HY, Wong LC. Symptoms, coping strategies, and timing of presentations in patients with newly diagnosed ovarian cancer. Gynecol Oncol. 2003;90:651–6.
8. Ferrell B, Smith S, Cullinane C, Melancon C. Symptom concerns of women with ovarian cancer. J Pain Symptom Manag. 2003;25:528–38.
9. Smith LH, Morris CR, Yasmeen S, et al. Ovarian cancer: can we make the clinical diagnosis earlier? Cancer. 2005;104:1398–407.
10. Webb PM, Purdie DM, Grover S, et al. Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer. Gynecol Oncol. 2004;92(1):232–9.
11. Wynn ML. Temporal patterns of conditions and symptoms potentially associated with ovarian cancer. J Womens Health (Larchmt). 2007;16:971–86.
12. Khan A, Sultana K. Presenting signs and symptoms of ovarian cancer at a tertiary care hospital. J Pak Med Assoc. 2010;60:260–2.
13. Behtash N, Ghayouri Azar E, Fakhrejahani F. Symptoms of ovarian cancer in young patients 2 years before diagnosis, a case–control study. Eur J Cancer Care. 2008;17:483–7.
14. Friedman G, Skilling JS, Udaltsova NV, Smith LH. Early symptoms of ovarian cancer: a case–control study without recall bias. Fam Pract. 2005;22:548–53.
15. Yawn BP, Barrette BA, Wollan PC. Ovarian cancer: the neglected diagnosis. Mayo Clin Proc. 2004;79:1277–82.
16. Lataifeh I, Marsden DE, Robertson G, et al. Presenting symptoms of epithelial ovarian cancer. Aust N Z J Obstet Gynaecol. 2005;45:211–14.
17. Lim MC, Chun KC, Shin SJ, et al. Clinical presentation of endometrioid epithelial ovarian cancer with concurrent endometriosis: a multicenter retrospective study. Cancer Epidemiol Biomarkers Prev. 2010;19:398–404.
18. Hamilton W, Peters TJ, Bankhead C, Sharp D. Risk of ovarian cancer in women with symptoms in primary care: population based case–control study. BMJ. 2009;339:b2998.
19. Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS. Predictive value of symptoms for early detection of ovarian cancer. J Nat Cancer Inst. 2010;102:222–9.
20. Ryerson AB, Eheman C, Burton J, et al. Symptoms, diagnoses, and time to key diagnostic procedures among older U.S. women with ovarian cancer. Obstet Gynecol. 2007;109:1053–61.
21. Devlin S, Diehr PH, Andersen MR, et al. Identification of ovarian cancer symptoms in health insurance claims data. J Womens Health (Larchmt). 2010;19:381–9.
22. Lurie G, Thompson PJ, McDuffie KE, Carney ME, Goodman MT. Prediagnostic symptoms of ovarian carcinoma: a case-control study. Gynecol Oncol. 2009;114:231–6.
23. Bankhead C, Collins C, Stokes-Lampard H, et al. Identifying symptoms of ovarian cancer: a qualitative and quantitative study. BJOG. 2008;115:1008–14.
24. Jayde V, White K, Blomfield P. Symptoms and diagnostic delay in ovarian cancer: a summary of the literature. Contemp Nurse. 2009;34:55–65.
25. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004;291:2705–12.
26. Olson SH, Mignone L, Nakraseive C, et al. Symptoms of ovarian cancer. Obstet Gynecol. 2001;98:212–7.
27. Olsen C, Cnossen J, Green AC, Webb PM. Comparison of symptoms and presentation of women with benign, low malignant potential and invasive ovarian tumors. Eur J Gynaecol Oncol. 2007;28:376–80.
28. Clarke-Pearson DL. Screening for ovarian cancer. N Engl J Med. 2009;361:170–7.
29. Liu JH. Management of the adnexal mass. Obstet Gynecol. 2011;117:1413–28.
30. Skírnisdóttir I, Garmo H, Holmberg L. Non-genital tract metastases to the ovaries presented as ovarian tumors in Sweden 1990–2003: occurrence, origin and survival compared to ovarian cancer. Gynecol Oncol. 2007;105:166–71.
31. Antila R, Jalkanen J, Heikinheimo O. Comparison of secondary and primary ovarian malignancies reveals differences in their pre- and perioperative characteristics. Gynecol Oncol. 2006;101:97–101.
32. Lewis MR, Euscher ED, Deavers MT, Silva EG, Malpica A. Metastatic colorectal adenocarcinoma involving the ovary with elevated serum CA125: A potential diagnostic pitfall. Gynecol Oncol. 2007;105:395–8.
33. Fishman DA, Cohen LS. Is transvaginal ultrasound effective for screening asymptomatic women for the detection of early-stage epithelial ovarian carcinoma? Gynecol Oncol. 2000;77:347–9.
34. Fishman DA, Cohen L, Blank SV, et al. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol. 2005;192:1214–21.
35. Cohen L, Fishman DA. Ultrasound and ovarian cancer. Cancer Treat Res. 2002;107:119–32.
36. Buy JN, Ghossain MA, Sciot C, et al. Epithelial tumors of the ovary: CT findings and correlation with US. Radiology. 1991;178:811–18.
37. Jain KA, Friedman DL, Pettinger TW, et al. Adnexal masses: comparison of specificity of endovaginal US and pelvic MR imaging. Radiology. 1993;186:697–704.
38. Hamper UM, Sheth S, Abbas FM, et al. Transvaginal color Doppler sonography of adnexal masses: differences in blood flow impedance in benign and malignant lesions. AJR Am J Roentgenol. 1993;160:1225–8.
39. Reles A, Wein U, Lichtenegger W. Transvaginal color Doppler sonography and conventional sonography in the preoperative assessment of adnexal masses. J Clin Ultrasound. 1997;25:217–25.
40. Marret H, Sauget S, Giraudeau B, et al. Contrast-enhanced sonography helps in discrimination of benign from malignant adnexal masses. J Ultrasound Med. 2004;23:1629–39.
41. Ordén MR, Jurvelin JS, Kirkinen PP. Kinetics of a US contrast agent in benign and malignant adnexal tumors. Radiology. 2003;226:405–10.
42. Aletti GD, Gallenberg MM, Cliby WA, Jatoi A, Hartmann LC. Current management strategies for ovarian cancer. Mayo Clin Proc. 2007;82:751–70.
43. Bharwani N, Reznek RH, Rockall AG. Ovarian cancer management: the role of imaging and diagnostic challenges. Eur J Radiol. 2011;78:41–51.
44. Fleischer AC. Recent advances in the sonographic assessment of vascularity and blood flow in gynecologic conditions. Am J Obstet Gynecol. 2005;193:294–301.
45. Goldberg BB. Contrast agents. Ultrasound Med Biol. 2000;26(Suppl 1):S33–4.
46. Burns PN, Hope Simpson D, Averkiou MA. Nonlinear imaging. Ultrasound Med Biol. 2000;26(Suppl 1):S19–22.
47. Brasch R. MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report. Eur J Radiol. 2000;34:148–55.
48. Leen E. Ultrasound contrast harmonic imaging of abdominal organs. Semin Ultrasound CT MRI. 2001;22:11–24.
49. Ferrara KW, Merritt CR, Burns PN, et al. Evaluation of tumor angiogenesis with US: imaging, Doppler, and contrast agents. Acad Radiol. 2000;7:824–39.
50. Hall GH. Use of dynamic contrast-enhanced MRI to assess the functional vascular pharmacokinetic parameters of normal human ovaries. J Reprod Med. 2002;47:107–14.
51. Huber S, Helbich T, Kettenbach J, et al. Effects of a microbubble contrast agent on breast tumors: computer-assisted quantitative assessment with color Doppler US – early experience. Radiology. 1998;208:485–9.
52. Furlow B. Contrast-enhanced ultrasound. Radiol Technol. 2009;80:547S–61S.
53. Eckersley RJ, Sedelaar JP, Blomley MJ, et al. Quantitative microbubble enhanced transrectal ultrasound as a tool for monitoring hormonal treatment of prostate carcinoma. Prostate. 2002;51:256–67.
54. Krix M, Kiessling F, Vosseler S, et al. Comparison of intermittent-bolus contrast imaging with conventional power Doppler sonography: quantification of tumour perfusion in small animals. Ultrasound Med Biol. 2003;29:1093–103.
55. Weinberg LE, Lurain JR, Singh DK, Schink JC. Survival and reproductive outcomes in women treated for malignant ovarian germ cell tumors. Gynecol Oncol. 2011;121:285–9.
56. Schorge JO, Williams JW. Williams’s Gynecology. New York: McGraw-Hill Medical; 2008.
57. Gershenson DM. Management of ovarian germ cell tumors. J Clin Oncol. 2007;25:2938–43.
58. Berek JS, Hacker NF. Practical Gynecologic Oncology. Baltimore: Lippincott Williams & Wilkins; 2000.
59. Madsen EM. Oophorectomy in the prevention of ovarian cancer. Acta Obstet Gynecol Scand. 1993;72:599–600.
60. Pastore M, Manci N, Marchetti C, et al. Late aortic lymphocele and residual ovary syndrome after gynecological surgery. World J Surg Oncol. 2007;5:146.
61. Dekel A, Efrat Z, Orvieto R, et al. The residual ovary syndrome: a 20-year experience. Eur J Obstet Gynecol Reprod Biol. 1996;68:159–64.
62. Magtibay PM, Magrina JF. Ovarian remnant syndrome. Clin Obstet Gynecol. 2006;49:526–34.
63. Narayansingh G, Cumming G, Parkin D, Miller I. Ovarian cancer developing in the ovarian remnant syndrome. A case report and literature review. Aust N Z J Obstet Gynaecol. 2000;40:221–3.
64. Brun JL. Demons syndrome revisited: a review of the literature. Gynecol Oncol. 2007;105:796–800.
65. Okuchi Y, Nagayama S, Mori Y, et al. VEGF hypersecretion as a plausible mechanism for pseudo-Meigs’ syndrome in advanced colorectal cancer. Jpn J Clin Oncol. 2010;40:476–81.
66. Cheng MH, Yen MS, Chao KC, Sheu BC, Wang PH. Differential diagnosis of gynecologic organ-related diseases in women presenting with ascites. Taiwanese J Obstet Gynecol. 2008;47:384–90.
67. Hlaise KK, Shingange SM. Sudden death associated with Meigs syndrome: an autopsy case report. Am J Forensic Med Pathol. 2012;33:58–60.
68. Jiang W, Lu X, Zhu ZL, Liu XS, Xu CJ. Struma ovarii associated with pseudo-Meigs’ syndrome and elevated serum CA 125: a case report and review of the literature. J Ovarian Res. 2010;3:18.
69. Kawakubo N, Okido M, Tanaka R, et al. Pseudo-Meigs’ syndrome associated with breast cancer metastasis to both ovaries: report of a case. Surg Today. 2010;40:1148–51.
70. Marci R, Giugliano E, Carboni S, Martinello R, Patella A. Pseudo-Meigs’ syndrome caused by a uterine leiomyosarcoma: a new clinical condition. Gynecol Obstet Invest. 2011;72:68–72.
71. Alsamarai S, Adams JM, Murphy MK, et al. Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age. J Clin Endocrinol Metab. 2009;94:4961–70.
72. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7:219–31.
73. Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91:456–88.
74. Bartoszek MP. Recognizing polycystic ovary syndrome in the primary care setting. Nurse Pract. 2009;34:22–9.
75. Wild RA. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010;95:2038–49.
76. Pesant MH, Baillargeon JP. Polycystic ovary syndrome and metabolic syndrome. In: Zeitler PS, Nadeau KJ (Eds.). Insulin Resistance. New York: Humana Press; 2009. p 245–61.
77. Dey R, Fleming R, Sattar N, Greer IA, Wallace AM. Association of metabolic syndrome in polycystic ovarian syndrome: an observational study. J Obst Gynecol India. 2011;61:176–81.
78. Pothiwala P, Jain SK, Yaturu S. Metabolic syndrome and cancer. Metab Syndr Relat Disord. 2009;7:279–88.
79. Somani N, Harrison S, Bergfeld WF. The clinical evaluation of hirsutism. Dermatol Ther. 2008;21:376–91.
80. Blanc F. [Werner’s syndrome with early onset with hyperandrogenism caused by ovarian hyperthecosis, acanthosis nigricans and peripheral neuropathy]. Ann Dermatol Venereol. 1990;117:785–6.
81. Wiedemann HR, Kunze J, Grosse FR. Clinical Syndromes. London: Mosby-Wolfe; 1997.
82. Keller J, Subramanyam L, Simha V, et al. Lipodystrophy: an unusual diagnosis in a case of oligomenorrhea and hirsutism. Obstet Gynecol. 2009;114(Pt 2):427–31.
83. Grunberger G, Alfonso B. Syndromes of extreme insulin resistance. In: Poretsky L (Ed.). Principles of Diabetes Mellitus. New York: Springer; 2010. p 259–77.
84. Oh CW, Yoon J, Kim CY. Malignant acanthosis nigricans associated with ovarian cancer. Case Rep Dermatol. 2010;2:103–9.
85. Mathur R, Evbuomwan I, Jenkins J. Prevention and management of ovarian hyperstimulation syndrome. 2005;15:132–8.
86. Zivi E. Ovarian hyperstimulation syndrome: definition, incidence, and classification. Semin Reprod Med. 2010;28:441–7.
87. Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril. 2006;85:112–20.
88. Zimmerman C. Ovarian hyperstimulation syndrome and development of pulmonary embolism in pregnancy: case report. Obstet Gynecol. 2010;1:1.
89. Aboulghar M. Treatment of ovarian hyperstimulation syndrome. Sem Reprod Med. 2010;28:532–9.
90. Tamai K, Koyama T, Saga T, et al. MR features of physiologic and benign conditions of the ovary. Eur Radiol. 2006;16:2700–11.
91. Gurgan T. Intravenous calcium infusion as a novel preventive therapy of ovarian hyperstimulation syndrome for patients with polycystic ovarian syndrome. Fertil Steril. 2011;96:53–7.
92. Spitzer D, Woqatzky J, Murtinger M, et al. Dopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome. Fertil Steril. 2011;95:2742–4.
93. Qublan H, Amarin Z, Nawasreh M, et al. Luteinized unruptured follicle syndrome: incidence and recurrence rate in infertile women with unexplained infertility undergoing intrauterine insemination. Hum Reprod. 2006;21:2110–3.
94. Shelling AN. Premature ovarian failure. Reproduction. 2010;140:633–41.
95. Vutyavanich T, Piromlertamorn W, Ellis J. Immature oocytes in “apparent empty follicle syndrome”: a case report. Case Report Med. 2010;2010:367505.
96. Soliman AT. Empty sellae, impaired testosterone secretion, and defective hypothalamic-pituitary growth and gonadal axes in children with Bardet-Biedl syndrome. Metab Clin Exp. 1996;45:1230–4.
97. Karaman A. Bardet-Biedl syndrome: a case report. Dermatology Online J. 2008;14:9.
98. Dumitrescu CE, Collins MT. McCune-Albright syndrome. Orphanet J Rare Dis. 2008;3:12.
99. Bhutta HY, Walsh SR, Tang TY, Walsh CA, Clarke JM. Ovarian vein syndrome: a review. Int J Surg. 2009;7:516–20.
100. Freedman J, Ganeshan A, Crowe PM. Pelvic congestion syndrome: the role of interventional radiology in the treatment of chronic pelvic pain. Postgrad Med J. 2010;86:704–10.
101. Burlet G, Judlin P. [Acute pelvic pain syndrome. Diagnostic and therapeutic approach in women]. Rev Fr Gynecol Obstet. 1994;89:537–42.
102. Cunningham JM, Feldman MD. Munchausen by internet: current perspectives and three new cases. Psychosomatics. 2011;52:185–9.
103. Chen CP, et al. Bilateral calcified ovarian fibromas in a patient with Sotos syndrome. Fertil Steril. 2002;77:1285–7.
104. Seracchioli R. Conservative treatment of recurrent ovarian fibromas in a young patient affected by Gorlin syndrome. Hum Reprod (Oxford). 2001;16(6):1261–3.
105. Scully RE, Young RH, Clement PB (Eds.). Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament. Atlas of Tumor Pathology. Third Series, Fascicle 23. Washington, DC: Armed Forces Institute of Pathology. 1998.
106. Morse CB, McLaren JF, Roy D, et al. Ovarian preservation in a young patient with Gorlin syndrome and multiple bilateral ovarian masses. Fertil Steril. 2011;96(1):e47–50.
107. Ball A, Wenning J, Van Eyk N. Ovarian fibromas in pediatric patients with basal cell nevus (Gorlin) syndrome. J Pediatr Adolesc Gynecol. 2011;24(1):e5–7.
108. Aram S. Bilateral ovarian fibroma associated with Gorlin syndrome. J Res Med Sci. 2009;14(1):57–61.
109. Hong JH. Unilateral ovarian dermoid cyst accompanied by an ipsilateral paratubal cyst in a girl with Proteus syndrome discovered by laparoscopic surgery. J Pediatr Adolesc Gynecol. 2010;23(3):107–10.
110. Jones KL, Smith DW. Smith’s Recognizable Patterns of Human Malformation. Philadelphia: Saunders; 1997.
111. Winter RM, Baraitser M. Multiple Congenital Anomalies: A Diagnostic Compendium: First Supplement. New York: Chapman & Hall Medical; 1993.
112. Mena W. Fused eyelids, airway anomalies, ovarian cysts, and digital abnormalities in siblings: a new autosomal recessive syndrome or a variant of Fraser syndrome? Am J Med Genet. 1991;40(3):377–82.
113. Wagner M, et al. Lipid cell tumors in two women with von Hippel-Lindau syndrome. Obstet Gynecol. 2010;116(Suppl 2):535–9.
114. Lee S. Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma. Gynecol Oncol. 2007;106(2):311–17.
115. Huffman C. Weaver syndrome with neuroblastoma and cardiovascular anomalies. Am J Med Genet. 2001;99(3):252–5.
116. Vieira SC, et al. Sclerosing peritonitis associated with luteinized thecoma and elevated serum CA 125 levels: case report. Sao Paulo Med J. 2008;126(2):123–5.
117. Koak Y. Idiopathic sclerosing peritonitis. Eur J Gastroenterol Hepatol. 2008;20(2):148–50.
118. Staats PN. Luteinized thecomas (thecomatosis) of the type typically associated with sclerosing peritonitis: a clinical, histopathologic, and immunohistochemical analysis of 27 cases. Am J Surg Pathol. 2008;32(9):1273–90.
119. Yamashita S, et al., Lymphangioleiomyomatosis suspected to be a gynecologic disease. J Obstet Gynecol Res. 2011;37(3):267–9.
120. Lodish MB. The differential diagnosis of familial lentiginosis syndromes. Fam Cancer. 2011;10:481–90.
121. Barker D. An unusual case of sex cord tumor with annular tubules with malignant transformation in a patient with Peutz-Jeghers syndrome. Int J Gynecol Pathol. 2010;29(1):27–32.
122. van Lier MGF, et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol. 2010;105(6):1258–64.
123. Tantipalakorn C, et al. Female genital tract tumors and gastrointestinal lesions in the Peutz-Jeghers syndrome. J Med Assoc Thai. 2009;92(12):1686–90.
124. Swanger RS. Ultrasound of ovarian sex-cord tumor with annular tubules. Ped Radiol. 2007;37(12):1270–1.
125. Howell L. Sertoli Leydig cell ovarian tumour and gastric polyps as presenting features of Peutz-Jeghers syndrome. Pediatr Blood Cancer. 2010;55(1):206–7.
126. Kato N, et al. Pyloric gland metaplasia/differentiation in multiple organ systems in a patient with Peutz-Jegher’s syndrome. Pathol Int. 2011;61(6):369–72.
127. Kilic-Okman T. Breast cancer, ovarian gonadoblastoma and cervical cancer in a patient with Peutz-Jeghers syndrome. Arch Gynecol Obstet. 2008;278(1):75–7.
128. D’costa GF, et al. Peutz-Jegher’s syndrome with ovarian serous cystadenoma: an unusual association. Indian J Pathol Microbiol. 2007;50(4):768–70.
129. Vasovcak P, et al. Multiple primary malignancies and subtle mucocutaneous lesions associated with a novel PTEN gene mutation in a patient with Cowden syndrome: case report. BMC Med Genet. 2011;12(1):38.
130. Babovic N, et al. Mucinous cystadenoma of ovary in a patient with juvenile polyposis due to 10q23 microdeletion: expansion of phenotype. Am J Med Genet A. 2010;152A(10):2623–7.
131. Lytras A, Tolis G. Reproductive disturbances in multiple neuroendocrine tumor syndromes. Endocr Relat Cancer. 2009;16(4):1125–38.
132. Boardman L, et al. Association of Peutz-Jeghers-like mucocutaneous pigmentation with breast and gynecologic carcinomas in women. Medicine (Baltimore). 2000;79(5):293–8.
133. Gell JS. Juvenile granulosa cell tumor in a 13-year-old girl with enchondromatosis (Ollier’s disease): a case report. J Pediatr Adolesc Gynecol. 1998;11(3):147–50.
134. Rietveld L, et al. First case of juvenile granulosa cell tumor in an adult with Ollier disease. Int J Gynecol Pathol. 2009;28(5):464–7.
135. La Vecchia C. Infertility, ovulation, induced ovulation, and female cancers. Eur J Cancer Prev. 2011;20(3):147–9.
136. Barber HR, Graber EA. The PMPO syndrome (postmenopausal palpable ovary syndrome). CA Cancer J Clin. 1972;22(6):357–9.
137. Djordjevic B. Growing teratoma syndrome of the ovary: review of literature and first report of a carcinoid tumor arising in a growing teratoma of the ovary. Am J Surg Pathol. 2007;31(12):1913–18.
138. Sengar AR, Kulkarni JN. Growing teratoma syndrome in a post laparoscopic excision of ovarian immature teratoma. J Gynecol Oncol. 2010;21(2):129–31.
139. Kikawa S, et al. Growing teratoma syndrome of the ovary: a case report with FDG -PET findings. J Obstet Gynecol Res. 2011;37(7):926–32.
140. Yahata T, et al. Tumor lysis syndrome associated with weekly paclitaxel treatment in a case with ovarian cancer. Gynecol Oncol. 2006;103(2):752–4.
141. Chong AL. Anaplastic large cell lymphoma of the ovary in a pediatric patient. J Pediatr Hematol Oncol. 2009;31(9):702–4.
142. Saluja M, Kenwright DN, Keating JP. Pseudomyxoma peritonei arising from a mucinous borderline ovarian tumour: case report and literature review. Aust N Z J Obstet Gynaecol. 2010;50(4):399–403.
143. Hwang JH, et al. Borderline-like mucinous tumor arising in mature cystic teratoma of the ovary associated with pseudomyxoma peritonei. Int J Gynecol Pathol. 2009;28(4):376–80.
144. Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin. 2002;52(2):72–91.
145. Gadducci A, et al. Malnutrition and cachexia in ovarian cancer patients: pathophysiology and management. Anticancer Res. 2001;21(4B):2941–7.
146. Smith J, Crowe K, McGaughran J, Robertson T. Sebaceous adenoma arising within an ovarian mature cystic teratoma in Muir–Torre syndrome. Ann Diagn Pathol. 2012;16:485–8.
147. Ehrsam EPJ, et al. Sweet’s syndrome associated with ovarian carcinoma. J Eur Acad Dermatol Venereol. 1993;2(3):235–8.
148. Bolke E, et al. Leser-Trelat sign presenting in a patient with ovarian cancer: a case report. J Med Case Reports. 2009;3:8583.
149. Veras E. Metastatic HPV-related cervical adenocarcinomas presenting with thromboembolic events (Trousseau syndrome): clinicopathologic characteristics of 2 cases. Int J Gynecol Pathol. 2009;28(2):134–9.
150. Athappilly GK, Braverman RS. Congenital alacrima in a patient with blepharophimosis syndrome. Ophthalmic Genet. 2009;30(1):37–9.
151. Satgé D, et al. An ovarian dysgerminoma in Down syndrome. Hypothesis about the association. Int J Gynecol Cancer. 2006;16(S1):375–9.
152. Kim SS. Peritoneal melanosis associated with mucinous cystadenoma of the ovary and adenocarcinoma of the colon. Int J Gynecol Pathol. 2010;29(2):113–16.
153. Lanjewar DN, Dongaonkar DD. HIV-associated primary non-Hodgkin’s lymphoma of ovary: A case report. Gynecol Oncol. 2006;102(3):590–2.
154. Santillan A, Bristow R. Paraneoplastic cerebellar degeneration in a woman with ovarian cancer. Nat Clin Pract Oncol. 2006;3(2):108–12; quiz.
155. Finsterer J, Voigtländer T, Grisold W. Deterioration of anti-Yo-associated paraneoplastic cerebellar degeneration. Neurol Sci. 2011;308:139–41.
156. Caliandro P, et al. Cerebellar degeneration and ocular myasthenia gravis in a patient with recurring ovarian carcinoma. Neurol Sci. 2010;31(1):79–81.
157. Stepanic V, et al. Ovarian cancer: PCD and brain metastases. Coll Antropol. 2007;31(2):633–6.
158. Monstad SE, et al. Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clin Exp Immunol. 2006;144(1):53–8.
159. Phuphanich S, Brock C. Neurologic improvement after high-dose intravenous immunoglobulin therapy in patients with paraneoplastic cerebellar degeneration associated with anti-Purkinje cell antibody. J Neurooncol. 2007;81(1):67–9.
160. Goldstein B, et al. Ovarian cancer and late onset paraneoplastic cerebellar degeneration. Arch Gynecol Obstet. 2009;280(1):99–101.
161. Bonakis A, et al. Acute onset paraneoplastic cerebellar degeneration. J Neurooncol. 2007;84(3):329–30.
162. Bradley W, Dottino P, Rahaman J. Paraneoplastic cerebellar degeneration in ovarian carcinoma: case report with review of immune modulation. Int J Gynecol Cancer. 2008;18(6):1364–7.
163. Singh V, Bhat I, Havlin K. Marantic endocarditis (NBTE) with systemic emboli and paraneoplastic cerebellar degeneration: uncommon presentation of ovarian cancer. J Neurooncol. 2007;83(1):81–3.
164. Fitzpatrick AS, et al. Opsoclonus-myoclonus syndrome associated with benign ovarian teratoma. Neurology. 2008;70(15):1292–3.
165. Tonomura Y, et al. Clinical analysis of paraneoplastic encephalitis associated with ovarian teratoma. J Neurooncol. 2007;84(3):287–92.
166. de Bot ST, et al. [From psychiatric symptoms to paraneoplastic syndrome]. Tijdschr Psychiatr. 2008;50(9):603–9.
167. Issa SS, Herskovitz S, Lipton RB. Acquired neuromyotonia as a paraneoplastic manifestation of ovarian cancer. Neurology. 2011;76(1):100–1.
168. Yumru A, et al. The relation between the presence of a giant primary ovarian leiomyoma and the occurrence of epilepsy as a paraneoplastic syndrome. Arch Gynecol Obstet. 2010;281(3):531–4.
169. Miranpuri AS, et al. Upper cervical intramedullary spinal metastasis of ovarian carcinoma: a case report and review of the literature. J Med Case Rep. 2011;5(1):311.
170. Cormio G, et al. Central nervous system metastases from epithelial ovarian cancer: prognostic factors and outcomes. Int J Gynecol Cancer. 2011;21(5):816–21.
171. Zahr Z, Baer A. Malignancy in myositis. Curr Rheumatol Rep. 2011;13(3):208–15.
172. Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010;85(9):838–54.
173. Venhuizen AC, Martens JE, Van Der Linden PJQ. Dermatomyositis as first presentation of ovarian cancer. Acta Obstet Gynecol Scand. 2006;85(10):1271–2.
174. Zhang W, Jiang SP, Huang L. Dermatomyositis and malignancy: a retrospective study of 115 cases. Eur Rev Med Pharmacol Sci. 2009;13(2):77–80.
175. Ghosh A, Malak T, Pool A. Polymyositis and ovarian carcinoma: a case report. Arch Gynecol Obstet. 2007;275(3):195–7.
176. Kalogiannidis I, et al. Clear cell ovarian carcinoma following polymyositis diagnosis: a case report and review of the literature. Hippokratia. 2008;12(3):181–5.
177. Thiers BH, Sahn RE, Callen JP. Cutaneous manifestations of internal malignancy. CA Cancer J Clin. 2009;59(2):73–98.
178. Scheinfeld N. A review of the cutaneous paraneoplastic associations and metastatic presentations of ovarian carcinoma. Clin Exp Dermatol. 2008;33(1):10–15.
179. Yilmaz Z, et al. Skin metastasis in ovarian carcinoma. Int J Gynecol Cancer. 2006;16(S1):414–8.
180. Kebria MM, et al. Malignant acanthosis nigricans, tripe palms and the sign of Leser-Tre’lat, a hint to the diagnosis of early stage ovarian cancer: a case report and review of the literature. Gynecol Oncol. 2006;101(2):353–5.
181. Cho M-Y. First report of ovarian dysgerminoma in Cowden syndrome with germline PTEN mutation and PTEN-related 10q loss of tumor heterozygosity. Am J Surg Pathol. 2008;32(8):1258–64.
182. Cannavó SP, et al. Simultaneous development and parallel course of disseminated superficial porokeratosis and ovarian cancer: coincidental association or true paraneoplastic syndrome? J Am Acad Dermatol. 2008;58(4):657–60.
183. Streiff MB, et al. Venous thromboembolic disease. J Natl Compr Canc Netw. 2011;9(7):714–77.
184. Tateo S, et al. Ovarian cancer and venous thromboembolic risk. Gynecol Oncol. 2005;99(1):119–25.
185. Iodice S, et al. Venous thromboembolic events and organ-specific occult cancers: a review and meta-analysis. J Thromb Haemost. 2008;6(5):781–8.
186. Satoh T, et al. High incidence of silent venous thromboembolism before treatment in ovarian cancer. Br J Cancer. 2007;97(8):1053–7.
187. Uno K, et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer. 2007;96(2):290–5.
188. White RH, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528 693 adults. Arch Intern Med. 2005;165(15):1782–7.
189. Mehta S. A rare paraneoplastic presentation of a functional ovarian tumor. J Pelvic Med Surg. 2008;14(5):405–7.
190. Peedicayil A, et al. Incidence and timing of venous thromboembolism after surgery for gynecological cancer. Gynecol Oncol. 2011;121(1):64–9.
191. Snijders MP, Morsink M, van Spronsen DJ, de Kievit-van der Heijden IM. Internal jugular vein thrombosis as paraneoplastic syndrome of primary ovarian non-Hodgkin’s lymphoma. Eur J Gynaecol Oncol. 2010;31:675–8.
192. Wada Y, et al. Paradoxical cerebral embolism as the initial symptom in a patient with ovarian cancer. J Stroke Cerebrovasc Dis. 2007;16(2):88–90.
193. Holthouse DJ, Robbins P, Watson P. Paradoxical embolism secondary to ovarian carcinoma resulting in stroke. J Clin Neurosci. 2004;11(2):194–6.
194. De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol. 2004;50(3):187–96.
195. Wakana K, Yasugi T, Nako Y, et al. Successful surgical treatment and chemotherapy for ovarian cancer in a patient with idiopathic thrombocytopenic purpura. Int J Clin Oncol. 2011;16:447–9.
196. Shimura K, Shimazaki C, Okano A, et al. [Therapy-related myeloid leukemia following platinum-based chemotherapy for ovarian cancer.] Rinsho Ketsueki. 2001;42(2):99–103.
197. Lee JW, Yang WS, Chung SY, et al. Aggressive systemic mastocytosis after germ cell tumor of the ovary: C-KIT mutation documentation in both disease states. J Pediatr Hematol Oncol. 2007;29(6):412–15.
198. Haddad LB, Laufer MR. Thrombocytosis associated with malignant ovarian lesions within a pediatric/adolescent population. J Pediatr Adolesc Gynecol. 2008;21(5):243–6.
199. Shanbhogue AKP, et al. Clinical syndromes associated with ovarian neoplasms: a comprehensive review. Radiographics. 2010;30(4):903–19.
200. Alabduljalil T. Paraneoplastic syndromes in neuro-ophthalmology. Curr Opin Ophthalmol. 2007;18(6):463–9.
201. Prefontaine M, Gragoudas ES. Blindness as a consequence of a paraneoplastic syndrome in a woman with clear cell carcinoma of the ovary. Gynecol Oncol. 1999;73(3):424–9.
202. O’Neal KD, et al. Bilateral diffuse uveal melanocytic proliferation associated with pancreatic carcinoma: a case report and literature review of this paraneoplastic syndrome. Survey Ophthalmol. 2003;48(6):613–25.
203. Duong HVQ, McLean IW, Beahm DE. Bilateral diffuse melanocytic proliferation associated with ovarian carcinoma and metastatic malignant amelanotic melanoma. Am J Ophthalmol. 2006;142(4):693–5.
204. Dykgraaf RHM, et al. Clinical management of ovarian small-cell carcinoma of the hypercalcemic type: a proposal for conservative surgery in an advanced stage of disease. Int J Gynecol Cancer. 2009;19(3):348–53.
205. Rovithi M, et al. Small cell ovarian cancer in adolescents: report of two cases and review of the literature. Case Report Med. 2011;2011:749516.
206. Clement PB. Selected miscellaneous ovarian lesions: small cell carcinomas, mesothelial lesions, mesenchymal and mixed neoplasms, and non-neoplastic lesions. Mod Pathol. 2005;18(Suppl 2):113–29.
207. Pressey JG. The treatment of small cell carcinoma of the ovary hypercalcemic type. Oncol Rev. 2010: 1–6 [published online: 17 September 2010].
208. Young RH, Goodman A, Penson RT, et al. Case records of the Massachusetts General Hospital. Case 8-2010. A 22-year-old woman with hypercalcemia and a pelvic mass. N Engl J Med. 2010;362(11):1031–40.
209. Wynn D, Everett GD, Boothby RA. Small cell carcinoma of the ovary with hypercalcemia causes severe pancreatitis and altered mental status. Gynecol Oncol. 2004;95(3):716–18.
210. Montalto SA, et al. Small cell carcinoma of the ovary: hypercalcaemic type. J Obstet Gynaecol. 2011;31(2):199–200.
211. Harrison M, et al. Small cell of the ovary, hypercalcemic type – Analysis of combined experience and recommendation for management. A GCIG study. Gynecol Oncol. 2006;100(2):233–8.
212. Piura B. [Hypercalcemia in malignancies of the female genital tract]. Harefuah. 2008;147(3):229–34.
213. Wysolmerski JJ, Broadus AE. Hypercalcemia of malignancy: the central role of parathyroid hormone-related protein. Ann Rev Med. 1994;45(1):189–200.
214. Klein M, Weryha G, Dousset B, et al. [Physiological role of PTHrP]. Ann Endocrinol (Paris). 1995;56:193–204.
215. Datta NS, Abou-Samra AB. PTH and PTHrP signaling in osteoblasts. Cell Signal. 2009;21(8):1245–54.
216. Bruns D. Parathyroid hormone-related protein in benign lesions. Am J Clin Pathol. 1996;105(4):377–9.
217. Suwaki N, et al. Parathyroid hormone related protein as a potential tumor marker: a case report of ovarian clear cell carcinoma. J Obstet Gynecol Res. 2006;32(1):94–8.
218. De Nuccio I, et al. Physiopathology of the renin-angiotensin system in the ovary. Minerva Endocrinol. 1999;24(2):77–81.
219. Rabban JT, et al. Primary ovarian carcinoid tumors may express CDX-2: a potential pitfall in distinction from metastatic intestinal carcinoid tumors involving the ovary. Int J Gynecol Pathol. 2009;28(1):41–8.
220. Cafà E, Angioli R, Scollo P. Ovarian carcinoid tumor with nodal metastases: case report. J Cancer Sci Ther. 2010;2:120–1.
221. Baldwin D. Cushing’s syndrome. In: Myers JA, Millikan KW, Saclarides TJ (Eds.). Common Surgical Diseases. New York: Springer; 2008. p 107–9.
222. Newell-Price J. Etiologies of Cushing’s syndrome. In: Bronstein MD (Ed.). Contemporary Endocrinology: Cushing’s Syndrome: Pathophysiology, Diagnosis and Treatment. Springer Science+Business Media. 2011. p 21–29.
223. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(5):1526–40.
224. Kim AW, Richter HM. Zollinger Ellison syndrome. In: Myers JA, Millikan KW, Saclarides TJ (Eds.). Common Surgical Diseases: An Algorithmic Approach to Problem Solving. Springer, 2008. p 123–6.
225. Hamm B, Forstner R, Beinder E. MRI and CT of the Female Pelvis. New York: Springer Verlag; 2007.
226. Abboud P, Bart H, Namsour G, et al. Ovarian gastrinoma in multiple endocrine neoplasia type I: a case report. Am J Obstet Gynecol. 2001;184(2):237–8.
227. D’Antonio A, et al. Hashimoto Thyroiditis as a manifestation of struma ovarii. Endocrinologist. 2010;20(5):220.
228. Lloyd RV. Endocrine Pathology: Differential Diagnosis and Molecular Advances. Totowa, NJ: Humana Press Inc; 2004.
229. Elsheikh M, Dunger DB, Conway GS, Wass JA. Turner’s syndrome in adulthood. Endocr Rev. 2002;23(1):120–40.
230. Gottlieb B, Beitel LK, Trifiro MA. Androgen Insensitivity Syndrome. Seattle, WA: University of Washington; 2007.
231. Peña-Alonso R, Nieto K, Alvarez R, et al. Distribution of Y-chromosome-bearing cells in gonadoblastoma and dysgenetic testis in 45, X/46, XY infants. Mod Pathol. 2004;18(3):439–45.
232. Blaustein A, Kurman RJ. Blaustein’s Pathology of the Female Genital Tract. New York: Springer Verlag; 2002.